Sugi Predict

Sugi Predict / Compounds / SCHEMBL9274644

SCHEMBL9274644

SCHEMBL9274644

COC(=O)C(C)c1ccc(N)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ ALOX5 P09917 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN2A Q99250 1/20 0.34
▸ SCN3A Q9NY46 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ ADRB2 P07550 1/20 0.33
▸ ADRB1 P08588 1/20 0.33
▸ ADRB3 P13945 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA5A P35218 1/20 0.33
▸ CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17827994 0.81 RAB9A (0.43) PTGS1PTGS2ALDH1A1KMT2AGAA
SCHEMBL23982614 0.80 KDM4E (0.41) ALDH1A1KMT2AKDM4EMEN1
SCHEMBL18148764 0.80 PTK2 (0.44) KMT2AHPGDMEN1
SCHEMBL6189387 0.76 PTGS2 (0.44) PTGS1PTGS2ALDH1A1KMT2AGAA
SCHEMBL17054858 0.76 LMNA (0.49) PTGS1ALDH1A1KMT2AADRB2ADRB1
SCHEMBL2182186 0.74 CNR2 (0.36) SLC6A3
SCHEMBL2170893 0.73 HPGD (0.50) PTGS1PTGS2SCN1ASCN2ASCN3A
SCHEMBL262458 0.73 HPGD (0.50) PTGS1PTGS2SCN1ASCN2ASCN3A
SCHEMBL1345587 0.73 HPGD (0.50) PTGS1PTGS2SCN1ASCN2ASCN3A
SCHEMBL1028262 0.72 CYP1A2 (0.57) PTGS1PTGS2ALDH1A1KMT2ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
EP-4227298-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF Technoderma Medicines Inc. (CN) 2023-08-16 — — EP disclosed
WO-2022073424-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF 嘉兴特科罗生物科技有限公司 2022-04-14 — — WO disclosed
WO-2022073424-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF 嘉兴特科罗生物科技有限公司 2022-04-14 — — WO disclosed
US-11197867-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2021-12-14 — — US disclosed
US-11197867-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2021-12-14 — — US disclosed
US-20210377495-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2021-12-02 — — US disclosed
US-20210377495-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2021-12-02 — — US disclosed
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2017-08-24 — — US disclosed
EP-3183247-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS Pfizer Inc (US) 2017-06-28 — — EP disclosed
US-9663526-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2017-05-30 — — US disclosed
US-9663526-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2017-05-30 — — US disclosed
US-9663526-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2017-05-30 — — US disclosed
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2016-02-25 — — US disclosed
WO-2016027195-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER INC. (US) 2016-02-25 — — WO disclosed
WO-1995033724-A1 PHENETHANOLAMINE DERIVATIVES AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 1995-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF JAK1, TYK2, JAK2 PTGS1 1359/4885PTGS2 1407/4885ALOX5 4102/4885
US-11197867-B2 Aminopyrimidinyl compounds CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 PTGS1 4400/4885PTGS2 4650/4885ALOX5 4088/4885
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 PTGS1 4353/4885PTGS2 4618/4885ALOX5 4268/4885
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 PTGS1 4353/4885PTGS2 4618/4885ALOX5 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.